FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, namely to an antibody or its antigen-binding fragment, capable of specifically recognizing polypeptide A related to a chain of major histocompatibility complex I class (MICA), a drug and a kit containing same, as well as to a method for production thereof. Also disclosed are a nucleic acid molecule coding said antibody or its antigen-binding fragment, as well as a vector and a cell containing same.
EFFECT: invention is effective for treating MICA-mediated disease, as well as for detecting MICA.
16 cl, 25 dwg, 3 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST A2 TENASTIN-C AND METHODS FOR USE THEREOF | 2011 |
|
RU2584597C2 |
| ANTI-CLAUDIN 18.2 ANTIBODY AND ITS ANTIBODY-DRUG CONJUGATE | 2022 |
|
RU2814164C2 |
| MICA/B ANTIBODIES AND METHODS OF USE | 2019 |
|
RU2821021C2 |
| ANTI-CD40-ANTIBODIES AND METHODS OF APPLICATION | 2012 |
|
RU2609647C2 |
| MICA BINDING AGENTS | 2013 |
|
RU2656183C2 |
| AFFINITY-MATURED HUMANISED ANTI-CEA MONOCLONAL ANTIBODIES | 2010 |
|
RU2570554C2 |
| ANTIBODIES AGAINST HUMAN CD19 WITH HIGH AFFINITY | 2016 |
|
RU2761077C1 |
| ANTIBODIES TO MST1R AND THEIR APPLICATION | 2010 |
|
RU2534890C2 |
| ANTIBODIES USEFUL IN DIAGNOSING CANCER | 2018 |
|
RU2815883C1 |
| HUMANIZED ANTI-VEGF MONOCLONAL ANTIBODY | 2020 |
|
RU2809746C2 |
